Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Allogene Therapeutics stock | 33.01

Own Allogene Therapeutics stock in just a few minutes.


Fact checked

Allogene Therapeutics, Inc is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Allogene Therapeutics employs 264 staff and has a market cap (total outstanding shares value) of USD$4.4 billion.

How to buy shares in Allogene Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Allogene Therapeutics. Find the stock by name or ticker symbol: ALLO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Allogene Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$33.01, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Allogene Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Allogene Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Allogene Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Allogene Therapeutics's share price has had significant positive movement.

Its last market close was USD$33.01, which is 21.21% up on its pre-crash value of USD$26.01 and 89.39% up on the lowest point reached during the March crash when the shares fell as low as USD$17.43.

If you had bought USD$1,000 worth of Allogene Therapeutics shares at the start of February 2020, those shares would have been worth USD$869.71 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,510.21.

Allogene Therapeutics share price

Use our graph to track the performance of ALLO stocks over time.

Allogene Therapeutics shares at a glance

Information last updated 2020-11-28.
Latest market close USD$33.01
52-week range USD$17.43 - USD$55
50-day moving average USD$34.1903
200-day moving average USD$38.4596
Wall St. target price USD$51.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.07

Buy Allogene Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Allogene Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Allogene Therapeutics price performance over time

Historical closes compared with the close of $33.01 from 2020-11-16

1 week (2020-11-23) 7.88%
1 month (2020-10-30) -2.68%
3 months (2020-08-28) -5.66%
6 months (2020-05-29) -31.46%
1 year (2019-11-29) 17.14%
2 years (2018-11-30) 5.53%
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Allogene Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -16.52%
Return on equity TTM -27.92%
Profit margin 0%
Book value $8.005
Market capitalisation USD$4.4 billion

TTM: trailing 12 months

Shorting Allogene Therapeutics shares

There are currently 10.6 million Allogene Therapeutics shares held short by investors – that's known as Allogene Therapeutics's "short interest". This figure is 5.1% up from 10.1 million last month.

There are a few different ways that this level of interest in shorting Allogene Therapeutics shares can be evaluated.

Allogene Therapeutics's "short interest ratio" (SIR)

Allogene Therapeutics's "short interest ratio" (SIR) is the quantity of Allogene Therapeutics shares currently shorted divided by the average quantity of Allogene Therapeutics shares traded daily (recently around 778845.03311258). Allogene Therapeutics's SIR currently stands at 13.59. In other words for every 100,000 Allogene Therapeutics shares traded daily on the market, roughly 13590 shares are currently held short.

However Allogene Therapeutics's short interest can also be evaluated against the total number of Allogene Therapeutics shares, or, against the total number of tradable Allogene Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allogene Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Allogene Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1259% of the tradable shares (for every 100,000 tradable Allogene Therapeutics shares, roughly 126 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Allogene Therapeutics.

Find out more about how you can short Allogene Therapeutics stock.

Allogene Therapeutics share dividends

We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.

Allogene Therapeutics share price volatility

Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $17.43 up to $55. A popular way to gauge a stock's volatility is its "beta".

ALLO.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 1.6311. This would suggest that Allogene Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Allogene Therapeutics overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site